Company Description
BirchBioMed is a clinical stage biopharmaceutical company focused on developing treatments for scarring (fibrosis, i.e., the overproduction and insufficient breakdown (or remodeling) of ECM proteins, predominantly collagen and fibronectin, within an organ) and related skin disorders; certain autoimmune diseases; and organ fibrosis.
We hold the exclusive, worldwide, non-perpetual pharmaceutical licenses from the University of British Columbia for two scientific technologies, FS1/FS2 and AI-001.
Based on preclinical studies and clinical trials we have conducted to date, we believe these technologies hold the potential for significant medical breakthroughs in the treatment of certain debilitating conditions/disorders in need of novel, better solutions.
| Country | Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Mark S. Miller |
Contact Details
Address: 130 Kingscross Drive King City, Ontario L7B 1E6 Canada | |
| Phone | 905-833-3414 |
| Website | birchbiomed.com |
Stock Details
| Ticker Symbol | BRBM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1670747 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark S. Miller | Chief Executive Officer and Chairman |
| Jon S. Verbeck | Chief Financial Officer |
| Carlos Camozzi, M.D., Ph.D. | Chief Medical Officer |
| Susan Elliott | Chief Operating Officer and Director |
| Teresa Bair | Director |
| Charles N. Ellis, M.D. | Director |
| Joseph Sardano | Director |
| James M. Jenkins | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 1, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 1, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 2, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 13, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 23, 2025 | DRS | [Cover] Draft Registration Statement |
| Oct 1, 2025 | D/A | Filing |
| Jul 11, 2025 | D | Notice of Exempt Offering of Securities |
| Jun 30, 2025 | 1-Z | Filing |
| May 15, 2025 | 1-A-W | Filing |